Jason Mayer, MD
Ophthalmology · Fort Collins, CONPI 1720374994
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), other and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $26,411 and has fallen 95.6% since, to $1,160 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $245.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Glaukos Corporation$9K
- Carl Zeiss Meditec, Inc.$2K
- Alcon$792
- Dompe US, Inc.$597
- Rxsight Inc$248
- plus $2K from 17 others
Across 56 payments — averaging $2229.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$125K
What the payments were for
- Consulting fees$7502%
- Speaking & faculty fees$23,98857%
- Travel & lodging$3,1798%
- Food & beverage$5,14612%
- Education$1,2503%
- Other$7,47518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $27,761 |
| Glaukos Corporation | 22 | $8,826 |
| Carl Zeiss Meditec, Inc. | 5 | $1,891 |
| Alcon | 24 | $792 |
| Dompe US, Inc. | 13 | $597 |
| Rxsight Inc | 3 | $248 |
| Harrow Eye, LLC | 2 | $237 |
| Tarsus Pharmaceuticals, Inc. | 6 | $216 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $202 |
| Biotissue Holdings Inc. | 3 | $196 |
| Bausch & Lomb Americas Inc. | 7 | $164 |
| Aerie Pharmaceuticals, Inc. | 2 | $139 |
| Novartis | 7 | $135 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $85 |
| Sun Pharmaceutical Industries Inc. | 3 | $78 |
| Eyevance Pharmaceuticals LLC | 3 | $49 |
| Rayner Intraocular Lenses Limited | 2 | $40 |
| Mallinckrodt Hospital Products Inc. | 2 | $28 |
| Omeros Corporation | 2 | $26 |
| Lensar, Inc. | 1 | $25 |
| Dutch Ophthalmic, USA | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$26,807
- VisuMax$1,836
- CE-marked KXLA system$750
- Oxervate$276
- VEVYE$221
- Photrexa Viscous and Photrexa$132
- ReSTOR$131
- ENVISTA$124
- Centurion$122
- RXSIGHT CONTACT LENS$118
- RXSIGHT INJECTOR CARTRIDGE$118
- RXSIGHT INJECTOR HANDPIECE$118
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$118
- LIGHT ADJUSTABLE LENS (LAL)$118
- Rhopressa$117
- Rocklatan$117
- XDEMVY$115
How this compares
$41,787 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 51 | $18,114 |
| Prednisolone Acetate | 556 | $17,958 |
| RestasisCyclosporine | 13 | $13,195 |
| Fluorometholone | 134 | $11,121 |
| MoxifloxacinMoxifloxacin Hcl | 385 | $9,826 |
| ValacyclovirValacyclovir Hcl | 104 | $7,871 |
| Cyclosporine | 12 | $7,726 |
| ZirganGanciclovir | 11 | $6,882 |
| Loteprednol Etabonate | 43 | $5,675 |
| Bromfenac Sodium | 31 | $5,300 |
| Ketorolac Tromethamine | 190 | $3,843 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $3,622 |
| Ofloxacin | 135 | $1,500 |
| Famciclovir | 12 | $701 |
| ErythromycinErythromycin Base | 49 | $675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $202 | $23,78994 claims |
| AbbVieRestasis, Combigan | $27,761 | $16,81724 claims |
| Bausch & Lomb Americas Inc.Zirgan | $164 | $6,88211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Fort Collins
- Gary FosterFort Collins$75K
- Karl OlsenFort Collins$15K
- Brittney StatlerFort Collins$8K
- Matthew AsanoFort Collins$4K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.